Tags

Type your tag names separated by a space and hit enter

The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom.
Front Immunol. 2021; 12:687869.FI

Abstract

To determine whether the neutralization activity of monoclonal antibodies, convalescent sera and vaccine-elicited sera was affected by the top five epidemic SARS-CoV-2 variants in the UK, including D614G+L18F+A222V, D614G+A222V, D614G+S477N, VOC-202012/01(B.1.1.7) and D614G+69-70del+N439K, a pseudovirus-neutralization assay was performed to evaluate the relative neutralization titers against the five SARS-CoV-2 variants and 12 single deconvolution mutants based on the variants. In this study, 18 monoclonal antibodies, 10 sera from convalescent COVID-19 patients, 10 inactivated-virus vaccine-elicited sera, 14 mRNA vaccine-elicited sera, nine RBD-immunized mouse sera, four RBD-immunized horse sera, and four spike-encoding DNA-immunized guinea pig sera were tested and analyzed. The N501Y, N439K, and S477N mutations caused immune escape from nine of 18 mAbs. However, the convalescent sera, inactivated virus vaccine-elicited sera, mRNA vaccine-elicited sera, spike DNA-elicited sera, and recombinant RBD protein-elicited sera could still neutralize these variants (within three-fold changes compared to the reference D614G variant). The neutralizing antibody responses to different types of vaccines were different, whereby the response to inactivated-virus vaccine was similar to the convalescent sera.

Authors+Show Affiliations

Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China. Wuhan Institute of Biological Products, Hubei, China.Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China. National Vaccine & Serum Institute, Beijing, China.Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China. Department of Pharmaceutical Engineering, College of Life Science and Technology, Dalian University, Dalian, China.Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China. Graduate School of Peking Union Medical College, Beijing, China.Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.Wuhan Institute of Biological Products, Hubei, China. Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.China National Biotec Group Company Limited, Beijing, China.Wuhan Institute of Biological Products, Hubei, China. National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, China.Translational Medicine Institute, First People's Hospital of Chenzhou, University of South China, Chenzhou, China.Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

34220844

Citation

Wu, Jiajing, et al. "The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom." Frontiers in Immunology, vol. 12, 2021, p. 687869.
Wu J, Zhang L, Zhang Y, et al. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. Front Immunol. 2021;12:687869.
Wu, J., Zhang, L., Zhang, Y., Wang, H., Ding, R., Nie, J., Li, Q., Liu, S., Yu, Y., Yang, X., Duan, K., Qu, X., Wang, Y., & Huang, W. (2021). The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. Frontiers in Immunology, 12, 687869. https://doi.org/10.3389/fimmu.2021.687869
Wu J, et al. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. Front Immunol. 2021;12:687869. PubMed PMID: 34220844.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. AU - Wu,Jiajing, AU - Zhang,Li, AU - Zhang,Yue, AU - Wang,Haixin, AU - Ding,Ruxia, AU - Nie,Jianhui, AU - Li,Qianqian, AU - Liu,Shuo, AU - Yu,Yongxin, AU - Yang,Xiaoming, AU - Duan,Kai, AU - Qu,Xiaowang, AU - Wang,Youchun, AU - Huang,Weijin, Y1 - 2021/06/17/ PY - 2021/03/30/received PY - 2021/05/24/accepted PY - 2021/7/5/entrez PY - 2021/7/6/pubmed PY - 2021/7/15/medline KW - B.1.1.7 KW - monoclonal antibody KW - mutation KW - neutralization KW - pseudotyped virus KW - vaccine SP - 687869 EP - 687869 JF - Frontiers in immunology JO - Front Immunol VL - 12 N2 - To determine whether the neutralization activity of monoclonal antibodies, convalescent sera and vaccine-elicited sera was affected by the top five epidemic SARS-CoV-2 variants in the UK, including D614G+L18F+A222V, D614G+A222V, D614G+S477N, VOC-202012/01(B.1.1.7) and D614G+69-70del+N439K, a pseudovirus-neutralization assay was performed to evaluate the relative neutralization titers against the five SARS-CoV-2 variants and 12 single deconvolution mutants based on the variants. In this study, 18 monoclonal antibodies, 10 sera from convalescent COVID-19 patients, 10 inactivated-virus vaccine-elicited sera, 14 mRNA vaccine-elicited sera, nine RBD-immunized mouse sera, four RBD-immunized horse sera, and four spike-encoding DNA-immunized guinea pig sera were tested and analyzed. The N501Y, N439K, and S477N mutations caused immune escape from nine of 18 mAbs. However, the convalescent sera, inactivated virus vaccine-elicited sera, mRNA vaccine-elicited sera, spike DNA-elicited sera, and recombinant RBD protein-elicited sera could still neutralize these variants (within three-fold changes compared to the reference D614G variant). The neutralizing antibody responses to different types of vaccines were different, whereby the response to inactivated-virus vaccine was similar to the convalescent sera. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/34220844/The_Antigenicity_of_Epidemic_SARS_CoV_2_Variants_in_the_United_Kingdom_ L2 - https://doi.org/10.3389/fimmu.2021.687869 DB - PRIME DP - Unbound Medicine ER -